人巨核细胞微颗粒在野生型小鼠体内诱导血小板生成
该研究在野生型BALB/c小鼠中证实,静脉输注2×10^6人巨核细胞微颗粒(huMkMPs)可在16小时后使血小板水平升高最多49%,并使诱导性血小板减少小鼠的血小板计数提高51%。huMkMPs可冻存,具有治疗血小板减少症及靶向造血干祖细胞递送货物的潜力。
要点
- huMkMPs静脉输注可在小鼠体内诱导新血小板生成。
- huMkMPs可改善诱导性血小板减少小鼠的低血小板水平。
- huMkMPs可冻存,并靶向骨髓等部位造血干祖细胞。
核心结论
- 人巨核细胞微颗粒(huMkMPs)可在野生型小鼠体内诱导体内的血小板生成,并改善诱导性血小板减少。
研究设计与样本
- 研究使用野生型BALB/c小鼠进行体内实验,并开展体外实验验证huMkMPs对小鼠造血干祖细胞(muHSPCs)的作用。
主要发现
- 体外实验显示,huMkMPs可在无血小板生成素条件下靶向muHSPCs并诱导其向巨核细胞分化。
- 静脉给予2×10^6 huMkMPs后16小时,小鼠血小板水平升高最多49%。
- 在诱导性血小板减少小鼠中,给予huMkMPs后16小时血小板计数提高51%。
- 生物分布实验显示,给药后24小时huMkMPs主要定位于骨髓、肺和肝。
- 除骨髓外,CD41+细胞在肺、脾、尤其是肝中频繁出现;在肝中huMkMPs与巨核祖细胞及muHSPCs共定位。
临床怎么用
- huMkMPs可冻存,有望作为治疗血小板减少症的可储存产品。
- huMkMPs可能作为体内靶向造血干祖细胞递送货物的载体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Platelet transfusions are used to treat idiopathic or drug-induced thrombocytopenia. Platelets are an expensive product in limited supply, with limited storage and distribution capabilities because they cannot be frozen. We have demonstrated that, in vitro, human megakaryocytic microparticles (huMkMPs) target human CD34+ hematopoietic stem and progenitor cells (huHSPCs) and induce their Mk differentiation and platelet biogenesis in the absence of thrombopoietin. In this study, we showed that, in vitro, huMkMPs can also target murine HSPCs (muHSPCs) to induce them to differentiate into megakaryocytes in the absence of thrombopoietin. Based on that, using wild-type BALB/c mice, we demonstrated that intravenously administering 2 × 106 huMkMPs triggered de novo murine platelet biogenesis to increase platelet levels up to 49% 16 hours after administration. huMkMPs also largely rescued low platelet levels in mice with induced thrombocytopenia 16 hours after administration by increasing platelet counts by 51%, compared with platelet counts in thrombocytopenic mice. Normalized on a tissue-mass basis, biodistribution experiments show that MkMPs localized largely to the bone marrow, lungs, and liver 24 hours after huMkMP administration. Beyond the bone marrow, CD41+ (megakaryocytes and Mk-progenitor) cells were frequent in lungs, spleen, and especially, liver. In the liver, infused huMKMPs colocalized with Mk progenitors and muHSPCs, thus suggesting that huMkMPs interact with muHSPCs in vivo to induce platelet biogenesis. Our data demonstrate the potential of huMkMPs, which can be stored frozen, to treat thrombocytopenias and serve as effective carriers for in vivo, target-specific cargo delivery to HSPCs.
引用
- Escobar C, Kao CY, Das S, et al. Human megakaryocytic microparticles induce de novo platelet biogenesis in a wild-type murine model. Blood Adv. 2020. PMID: 32119736. doi:10.1182/bloodadvances.2019000753
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。